Trial Profile

Phase Ib trial assessing STAR-0310 in patients with AD

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jan 2026 According to a BioCryst Pharmaceuticals media release, Astria Therapeutics has been acquired and merged into BioCryst Pharmaceutical.
18 Oct 2023 New trial record
11 Oct 2023 According to Astria Therapeutics media release, pending positive results from the Phase 1a clinical trial, Astria plans to initiate a Phase 1b clinical trial in patients with AD shortly thereafter, with initial results anticipated in second quarter of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com